Olema Pharmaceuticals Inc. (NASDAQ: OLMA) Faces Challenges Amidst Recent Clinical Study Results

Font: Financial Modeling Prep  • Mar 09, 2026

• Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is focused on developing targeted therapies for women's cancers, with collaborations with Pfizer Inc. and Novartis AG.
• Despite a recent price target of $38 by H.C. Wainwright, Olema's stock has declined to $16.30, influenced by disappointing results from Roche Holdings AG's phase 3 persevERA Breast Cancer study.
• Olema's stock shows significant volatility, with a year's trading range between $2.86 and $36.26, and a market capitalization of approximately $1.28 billion.

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is a biopharmaceutical company dedicated to the development of targeted therapies for women's cancers, particularly breast cancer. The company's leading project, Palazestrant, represents a new class of treatments as a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). Olema's strategic collaborations with pharmaceutical giants like Pfizer Inc. and Novartis AG underscore its commitment to advancing its clinical trials.

On March 9, 2026, Emily Bodnar from H.C. Wainwright set a price target of $38 for OLMA, indicating a potential upside of approximately 69% from its then-current trading price of $16.45. However, the stock has recently faced a downturn, now trading at $16.30, marking a decrease of 24.36% with a change of $5.25. This decline is attributed to recent data from Roche Holdings AG's phase 3 persevERA Breast Cancer study, which did not meet its primary endpoint of demonstrating a statistically significant improvement in progression-free survival. The study's outcome has adversely affected Olema's stock, given the similarity between Roche's giredestrant and Olema's Palazestrant.

Despite these challenges, Olema's stock has experienced significant fluctuations, with a daily low of $12.99 and a high of $18.62. Over the past year, the stock has ranged from a low of $2.86 to a high of $36.26, highlighting its volatile nature. With a market capitalization of approximately $1.28 billion and a trading volume of 11.89 million shares today, Olema continues to attract active investor interest despite recent setbacks.